The R-Pharm Group of Companies presented the results of a study of olokizumab, a drug for the treatment of rheumatoid arthritis. The study participants were children with juvenile idiopathic arthritis. The results were published in the scientific medical journal “Problems of Practical Pediatrics”.
Adolescents aged 12-17 years with juvenile idiopathic arthritis, manifested by polyarthritis, took part in phase II of the open clinical study (CT) of the pharmacokinetics, safety and efficacy of olokizumab. They received subcutaneous injections of olokizumab once every four weeks for 24 weeks. The response to therapy was noted after two weeks and lasted up to and including the 24th week. During the observation period, not a single exacerbation of the disease was registered, the patients’ well-being improved according to their parents.
“The obtained results indicate the potential effectiveness of olokizumab for children with juvenile idiopathic arthritis. The more therapeutic options are in the hands of pediatric rheumatologists, the more children we will be able to ensure full development. We are currently continuing the study in the younger group of patients,” said Mikhail Samsonov, medical director of the R-Pharm group.